Unicycive Therapeutics (UNCY)

• Market cap: $56.6M
• 1 day: -4.73%
• 5 days: -11.40%
• 1 month: -33.68%
• 3 months: -27.38%
• 6 months: -32.26%
• Year to date: -44.07%
• 1 year: 8.85%
• 5 years: -92.43%
• 10 years: -92.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

1.71% less ownership

Funds ownership: 59.44% [Q4 2024] → 57.73% (-1.71%) [Q1 2025]

6% less funds holding

Funds holding: 31 [Q4 2024] → 29 (-2) [Q1 2025]

30% less capital invested

Capital invested by funds: $49M [Q4 2024] → $34.5M (-$14.6M) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 1,254% upside
• Avg. target: $75 1,593% upside
• High target: $90 1,932% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth	1,932% upside $90	Buy Assumed	27 May 2025
Guggenheim Vamil Divan	1,254% upside $60	Buy Initiated	21 Apr 2025